← Back to Clinical Trials
Recruiting NCT05452291

NCT05452291 Multiomics Biomarkers for Urolithiasis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05452291
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Urolithiasis
Study Type OBSERVATIONAL
Enrollment 1,200 participants
Start Date 2022-05-27
Primary Completion 2024-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,200 participants in total. It began in 2022-05-27 with a primary completion date of 2024-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a prospective case series study. To compare urine sample of recurrent stone-formers and non-stone former by multiomics approach to identify potential markers for stone recurrence.

Eligibility Criteria

Inclusion Criteria: * Patients with history of recurrent urinary stone * Age greater than or equal to 18 years old * Have more than 2 episodes of radio-opaque stone disease (bilateral stones were counted as two episode) Patients with no history of urinary stone disease * Age greater than or equal to 18 years old * With no history of urinary calculi, from history and imaging. Exclusion criteria: * Patient refused or unable to provide consent for the study * Patient with active urinary infection * Patient with radiolucent stone or infective stone * Patients with no history of urinary stone disease (for control group) * Patient refused or unable to provide consent for the study * Patient with active urinary infection

Contact & Investigator

Central Contact

Chi Fai NG, MD

✉ ngcf@surgery.cuhk.edu.hk

📞 35052625

Principal Investigator

Chi Fai NG, MD

PRINCIPAL INVESTIGATOR

Chinese University of Hong Kong

Frequently Asked Questions

Who can join the NCT05452291 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Urolithiasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05452291 currently recruiting?

Yes, NCT05452291 is actively recruiting participants. Contact the research team at ngcf@surgery.cuhk.edu.hk for enrollment information.

Where is the NCT05452291 trial being conducted?

This trial is being conducted at Shatin, Hong Kong.

Who is sponsoring the NCT05452291 clinical trial?

NCT05452291 is sponsored by Chinese University of Hong Kong. The principal investigator is Chi Fai NG, MD at Chinese University of Hong Kong. The trial plans to enroll 1,200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology